Combination of 5-flucytosine and capsule-binding monoclonal antibody in the treatment of murine Cryptococcus neoformans infections and in vitro.
The efficacy of combination therapy with 5-flucytosine and an IgG1 monoclonal antibody to Cryptococcus neoformans capsular glucuronoxylomannan was studied in vitro with J774. 16 murine macrophage-like cells and in vivo in murine cryptococcal infection. The combination of 5-flucytosine and IgG1 was more effective in reducing the numbers of C. neoformans colony-forming units in vitro and in vivo than either agent alone.